Home/Filings/4/0000899243-21-018116
4//SEC Filing

Asanuma Sakae 4

Accession 0000899243-21-018116

CIK 0001785530other

Filed

May 3, 8:00 PM ET

Accepted

May 4, 4:31 PM ET

Size

16.2 KB

Accession

0000899243-21-018116

Insider Transaction Report

Form 4
Period: 2020-12-23
Asanuma Sakae
Director10% Owner
Transactions
  • Conversion

    Common Stock

    2021-05-04+1,318,3111,318,311 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-05-04+438,0981,756,409 total(indirect: See footnote)
  • Purchase

    Common Stock

    2021-05-04$16.00/sh+312,500$5,000,0002,068,909 total(indirect: See footnote)
  • Purchase

    Series B Preferred Stock

    2020-12-23$0.92/sh+3,797,921$3,499,4043,797,921 total(indirect: See footnote)
    Common Stock (438,098 underlying)
  • Conversion

    Series B Preferred Stock

    2021-05-043,797,9210 total(indirect: See footnote)
    Common Stock (438,098 underlying)
  • Conversion

    Series A Preferred Stock

    2021-05-0411,428,5700 total(indirect: See footnote)
    Common Stock (1,318,311 underlying)
Footnotes (4)
  • [F1]On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  • [F2]The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC.
  • [F3]On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  • [F4]The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Issuer

Werewolf Therapeutics, Inc.

CIK 0001785530

Entity typeother

Related Parties

1
  • filerCIK 0001857822

Filing Metadata

Form type
4
Filed
May 3, 8:00 PM ET
Accepted
May 4, 4:31 PM ET
Size
16.2 KB